Cornercap Investment Counsel Inc. Sells 412 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cornercap Investment Counsel Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,434 shares of the medical research company’s stock after selling 412 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Charles River Laboratories International were worth $339,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. VisionPoint Advisory Group LLC increased its stake in Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC bought a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $37,000. Operose Advisors LLC bought a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $42,000. Covestor Ltd increased its stake in Charles River Laboratories International by 100.0% during the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock worth $49,000 after purchasing an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after purchasing an additional 112 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $229.90 on Thursday. The business’s 50-day moving average price is $253.47 and its 200-day moving average price is $220.92. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The firm has a market capitalization of $11.84 billion, a price-to-earnings ratio of 24.96, a PEG ratio of 1.85 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.98 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have weighed in on CRL. Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. UBS Group upped their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Argus upped their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, Evercore ISI upped their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).